Literature DB >> 16292767

The biocompatibility of silk fibroin films containing sulfonated silk fibroin.

Xilan Ma1, Chuanbao Cao, Hesun Zhu.   

Abstract

Sulfonation reaction may be an effective method for preparation of heparin-like materials. However, no sulfonated polymer based on protein backbone was used for improving the blood compatibility of biomaterials. In this study, the biocompatibility of new kind of composite materials films obtained by blending silk fibroin (SF) with sulfonated silk fibroin (SSF) was evaluated. The anticoagulant activity was characterized with prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT), which all increased remarkably, the clot times exceeded the measurement limit of clot detection instrument. Its platelet adhesion was also investigated as another parameter of blood compatibility. The cell compatibility of composite films was evaluated through cell morphologies on the films and cell viability by methyl thiazolyl tetrazolium (MTT) assay. Tensile strength and elongation at break of the composite films reached to 44.6 MPa and 50.3%, respectively. All these results indicated that SF/SSF composite film was a potential material for blood-contact materials and tissue engineering matrix.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16292767     DOI: 10.1002/jbm.b.30466

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  11 in total

1.  In vivo histocompatibility evaluation of polyurethane membrane modified by superfine silk-fibroin powder.

Authors:  Chenxi Ouyang; Haiye Xu; Weici Wang; Hongjun Yang; Weilin Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-08-07

2.  Focal therapy of neuroblastoma using silk films to deliver kinase and chemotherapeutic agents in vivo.

Authors:  F Philipp Seib; Jeannine Coburn; Ilona Konrad; Nikolai Klebanov; Gregory T Jones; Brian Blackwood; Alain Charest; David L Kaplan; Bill Chiu
Journal:  Acta Biomater       Date:  2015-04-08       Impact factor: 8.947

3.  Biomedical applications of chemically-modified silk fibroin.

Authors:  Amanda R Murphy; David L Kaplan
Journal:  J Mater Chem       Date:  2009-06-23

4.  Chemical Modification of Silk Fibroin through Serine Amino Acid Residues.

Authors:  Xiuying Liu; Qianna Xia; Jiao Zhou; Yanbo Zhang; Haiyan Ju; Zhongmin Deng
Journal:  Materials (Basel)       Date:  2022-06-22       Impact factor: 3.748

5.  Multifunctional silk-heparin biomaterials for vascular tissue engineering applications.

Authors:  F Philipp Seib; Manuela Herklotz; Kelly A Burke; Manfred F Maitz; Carsten Werner; David L Kaplan
Journal:  Biomaterials       Date:  2013-10-04       Impact factor: 12.479

6.  Doxorubicin-loaded silk films: drug-silk interactions and in vivo performance in human orthotopic breast cancer.

Authors:  F Philipp Seib; David L Kaplan
Journal:  Biomaterials       Date:  2012-08-24       Impact factor: 12.479

7.  Development of a dinutuximab delivery system using silk foams for GD2 targeted neuroblastoma cell death.

Authors:  Kimberly J Ornell; Bill Chiu; Jeannine M Coburn
Journal:  J Biomed Mater Res A       Date:  2020-12-10       Impact factor: 4.854

8.  Hemocompatibility improvement of perfusion-decellularized clinical-scale liver scaffold through heparin immobilization.

Authors:  Ji Bao; Qiong Wu; Jiu Sun; Yongjie Zhou; Yujia Wang; Xin Jiang; Li Li; Yujun Shi; Hong Bu
Journal:  Sci Rep       Date:  2015-06-01       Impact factor: 4.379

9.  Random lasing and amplified spontaneous emission from silk inverse opals: Optical gain enhancement via protein scatterers.

Authors:  Muhammad Umar; Kyungtaek Min; Sookyoung Kim; Sunghwan Kim
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

10.  Silk film culture system for in vitro analysis and biomaterial design.

Authors:  Brian D Lawrence; Zhi Pan; Michael D Weber; David L Kaplan; Mark I Rosenblatt
Journal:  J Vis Exp       Date:  2012-04-24       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.